Search in:

Scandinavian Journal of Gastroenterology Volume 33, 1998 - Issue 6

Submit an article Journal homepage

Views

CrossRef citations to date

Altmetric

Research Article

Markers of Coagulation and Fibrinolysis as Measures of Disease Activity in Inflammatory Bowel Disease

J. KJELDSEN, J. F. LASSEN, I. BRANDSLUND, O. B. SCHAFFALITZKY DE MUCKADELL

Pages 637-643 | Published online: 08 Jul 2009

Cite this article
https://doi.org/10.1080/00365529850171927

References
Citations
Metrics
Reprints & Permissions

Citations (38)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Articles from other publishers (38)

Andrea Boccatonda, Marco Balletta, Susanna Vicari, Ariela Hoxha, Paolo Simioni & Elena Campello. (2022) The Journey Through the Pathogenesis and Treatment of Venous Thromboembolism in Inflammatory Bowel Diseases: A Narrative Review. Seminars in Thrombosis and Hemostasis.
Crossref

Tae Sik Sung, Suk Bae Moon, Brian A. Perrino, Kenton M. Sanders & Sang Don Koh. (2022) Altered functional responses by PAR1 agonist in murine dextran sodium sulphate-treated colon. Scientific Reports 12:1.
Crossref

Nidah Shabbir Khakoo, Stephanie Ioannou, Nabiha Shabbir Khakoo, Shyam Vedantam & Michelle Pearlman. (2022) Impact of Obesity on Inflammatory Bowel Disease. Current Gastroenterology Reports 24:1, pages 26-36.
Crossref

Eden Story, Vid Bijelic, Chelsea Penney, Eric I. Benchimol, Jacqueline Halton & David R. Mack. (2021) Safety of Venous Thromboprophylaxis With Low-molecular-weight Heparin in Children With Ulcerative Colitis. Journal of Pediatric Gastroenterology & Nutrition 73:5, pages 604-609.
Crossref

Jeremy Lagrange, Patrick Lacolley, Denis Wahl, Laurent Peyrin-Biroulet & Véronique Regnault. (2021) Shedding Light on Hemostasis in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 19:6, pages 1088-1097.e6.
Crossref

Jasmijn A. M. Sleutjes, Jeanine E. Roeters van Lennep, C. Janneke van der Woude & Annemarie C. de Vries. (2021) Thromboembolic and atherosclerotic cardiovascular events in inflammatory bowel disease: epidemiology, pathogenesis and clinical management. Therapeutic Advances in Gastroenterology 14, pages 175628482110321.
Crossref

Jeffrey D McCurdy, M Ellen Kuenzig, Glenys Smith, Sarah Spruin, Sanjay K Murthy, Marc Carrier, Geoffrey C Nguyen & Eric I Benchimol. (2020) Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases 26:11, pages 1761-1768.
Crossref

Mariana Ferreira-Duarte, Joana Beatriz Sousa, Carmen Diniz, Teresa Sousa, Margarida Duarte-Araújo & Manuela Morato. (2020) Experimental and Clinical Evidence of Endothelial Dysfunction in Inflammatory Bowel Disease. Current Pharmaceutical Design 26:30, pages 3733-3747.
Crossref

Katsuyoshi AndoMikihiro FujiyaYoshiki NomuraYuhei InabaYuuya SugiyamaTakuya IwamaMasami IjiriKeitaro TakahashiKazuyuki TanakaAki SakataniNobuhiro UenoShin KashimaKentaro MoriichiYusuke MizukamiToshikatsu Okumura. (2018) The incidence and risk factors of venous thromboembolism in Japanese inpatients with inflammatory bowel disease: a retrospective cohort study. Intestinal Research 16:3, pages 416.
Crossref

Huseyin Alkim, Ali Riza Koksal, Salih Boga, Ilker Sen & Canan Alkim. (2016) Etiopathogenesis, Prevention, and Treatment of Thromboembolism in Inflammatory Bowel Disease. Clinical and Applied Thrombosis/Hemostasis 23:6, pages 501-510.
Crossref

Hyun Jung Lee, Jae Hyun Kim, Seung Won Kim, Hyun Ah Joo, Hye Won Lee, You Sun Kim, Soo Jung Park, Sung Pil Hong, Tae Il Kim, Won Ho Kim, Young-Ho Kim & Jae Hee Cheon. (2017) Proteomic Analysis of Serum Amyloid A as a Potential Marker in Intestinal Behçet’s Disease. Digestive Diseases and Sciences 62:8, pages 1953-1962.
Crossref

Steven R. Lentz. (2016) Thrombosis in the setting of obesity or inflammatory bowel disease. Hematology 2016:1, pages 180-187.
Crossref

Steven R. Lentz. (2016) Thrombosis in the setting of obesity or inflammatory bowel disease. Blood 128:20, pages 2388-2394.
Crossref

Yavuz Beyazit, Abdurrahim Sayilir, Alpaslan Tanoglu, Murat Kekilli, Erdem Kocak, Fuat Ekiz & Adnan Tas. (2016) Plasma Thrombin-activatable Fibrinolysis Inhibitor Levels Correlate with the Disease Activity of Ulcerative Colitis. Internal Medicine 55:14, pages 1831-1836.
Crossref

Danuta Owczarek, Anetta Undas, Jonathan H. Foley, Michael E. Nesheim, Konrad Jabłonski & Tomasz Mach. (2012) Activated thrombin activatable fibrinolysis inhibitor (TAFIa) is associated with inflammatory markers in inflammatory bowel diseases. Journal of Crohn's and Colitis 6:1, pages 13-20.
Crossref

Huseyin Alkim, Selime Ayaz, Canan Alkim, Aysel Ulker & Burhan Sahin. (2011) Continuous Active State of Coagulation System in Patients With Nonthrombotic Inflammatory Bowel Disease. Clinical and Applied Thrombosis/Hemostasis 17:6, pages 600-604.
Crossref

S. Lipinski, L. Bremer, T. Lammers, F. Thieme, S. Schreiber & P. Rosenstiel. (2017) Coagulation and inflammation. Hämostaseologie 31:02, pages 94-104.
Crossref

B. VAN ZAANE, E. NUR, A. SQUIZZATO, V.E.A. GERDES, H.R. BÜLLER, O.M. DEKKERS & D.P.M. BRANDJES. (2010) Systematic review on the effect of glucocorticoid use on procoagulant, anti‐coagulant and fibrinolytic factors. Journal of Thrombosis and Haemostasis 8:11, pages 2483-2493.
Crossref

Jun Shen, Zhi Hua Ran, Yao Zhang, Qing Cai, Hong Min Yin, Xiao Tian Zhou & Shu Dong Xiao. (2009) Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: A gender-stratified, cohort analysis. Thrombosis Research 123:4, pages 604-611.
Crossref

Keiichiro Kume, Masahiro Yamasaki, Mitsuo Tashiro, Ichiro Yoshikawa & Makoto Otsuki. (2007) Activations of Coagulation and Fibrinolysis Secondary to Bowel Inflammation in Patients with Ulcerative Colitis. Internal Medicine 46:17, pages 1323-1330.
Crossref

P. ZEZOS, G. PAPAIOANNOU, N. NIKOLAIDIS, K. PATSIAOURA, A. PAPAGEORGIOU, T. VASSILIADIS, O. GIOULEME & N. EVGENIDIS. (2006) Low-molecular-weight heparin (enoxaparin) as adjuvant therapy in the treatment of active ulcerative colitis: a randomized, controlled, comparative study. Alimentary Pharmacology and Therapeutics 23:10, pages 1443-1453.
Crossref

Claire Jacob, Ping-Chang Yang, Dalila Darmoul, Silvia Amadesi, Toshiyuki Saito, Graeme S. Cottrell, Anne-Marie Coelho, Pamela Singh, Eileen F. Grady, Mary Perdue & Nigel W. Bunnett. (2005) Mast Cell Tryptase Controls Paracellular Permeability of the Intestine. Journal of Biological Chemistry 280:36, pages 31936-31948.
Crossref

Georg Aue, Nancy Carroll, Bruce R. Kressel, Robert Hardi & McDonald K. HorneIIIIII. (2005) Disseminated intravascular coagulation in an ambulatory young woman. Journal of Laboratory and Clinical Medicine 146:3, pages 192-196.
Crossref

Petros Zezos. (2005) Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World Journal of Gastroenterology 11:48, pages 7639.
Crossref

Nathalie Vergnolle, Laurie Cellars, Andrea Mencarelli, Giovanni Rizzo, Sunita Swaminathan, Paul Beck, Martin Steinhoff, Patricia Andrade-Gordon, Nigel W. Bunnett, Morley D. Hollenberg, John L. Wallace, Giuseppe Cirino & Stefano Fiorucci. (2004) A role for proteinase-activated receptor–1 in inflammatory bowel diseases. Journal of Clinical Investigation 114:10, pages 1444-1456.
Crossref

SANJAY KUMAR, UDAY C GHOSHAL, RAKESH AGGARWAL, VIVEK A SARASWAT & GOURDAS CHOUDHURI. (2004) Severe ulcerative colitis: Prospective study of parameters determining outcome. Journal of Gastroenterology and Hepatology 19:11, pages 1247-1252.
Crossref

S. Saibeni, B. Bottasso, L. Spina, M. Bajetta, S. Danese, A. Gasbarrini, R. de Franchis & M. Vecchi. (2004) Assessment of Thrombin-Activatable Fibrinolysis Inhibitor (TAFI) Plasma Levels in Inflammatory Bowel Diseases. The American Journal of Gastroenterology 99:10, pages 1966-1970.
Crossref

M. Sans, D. Tàssies, M. PellisÉ, G. Espinosa, L. Quintó, J. M. Piqué, J. C. Reverter & J. Panés. (2003) The 4G/4G genotype of the 4G/5G polymorphism of the type-1 plasminogen activator inhibitor (PAI-1) gene is a determinant of penetrating behaviour in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics 17:8, pages 1039-1047.
Crossref

Anton A. Vrij, Joop Rijken, Jan W.J. van Wersch & Reinhold W. Stockbrügger. (2003) Coagulation and Fibrinolysis in Inflammatory Bowel Disease and in Giant Cell Arteritis. Pathophysiology of Haemostasis and Thrombosis 33:2, pages 75-83.
Crossref

Ad A. van Bodegraven, Marianne Schoorl, Ronald K. Linskens, Piet C. Bartels & Hans A. Tuynman. (2002) Persistent activation of coagulation and fibrinolysis after treatment of active ulcerative colitis. European Journal of Gastroenterology & Hepatology 14:4, pages 413-418.
Crossref

Torben Bjerregaard Larsen, Jens Nederby Nielsen, Lisbeth Fredholm, Erik D. Lund, Ivan Brandslund, Pia Munkholm & Henrik Hey. (2002) Platelets and Anticoagulant Capacity in Patients with Inflammatory Bowel Disease. Pathophysiology of Haemostasis and Thrombosis 32:2, pages 92-96.
Crossref

Ad A. van Bodegraven & Stephan G. M. Meuwissen. (2001) Lipoprotein (a), thrombophilia and inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 13:12, pages 1407-1409.
Crossref

Ad A van Bodegraven, Marianne Schoorl, Jan P A Baak, R K Linskens, Piet C M Bartels & Hans A R E Tuynman. (2001) Hemostatic Imbalance in Active and Quiescent Ulcerative Colitis. American Journal of Gastroenterology 96:2, pages 487-493.
Crossref

PETER L. BEYER. 2001. Nutrition in the Prevention and Treatment of Disease. Nutrition in the Prevention and Treatment of Disease 577 599 .

Marla C. Dubinsky & Ernest G. Seidman. (2000) Diagnostic markers of inflammatory bowel disease. Current Opinion in Gastroenterology 16:4, pages 337-342.
Crossref

I.E. Koutroubakis. (2000) Role of Thrombotic Vascular Risk Factors in Inflammatory Bowel Disease. Digestive Diseases 18:3, pages 161-167.
Crossref

B White, YS Ang, N Mahmud, PWN Keeling & OP Smith. (1999) Heparin and inflammatory bowel disease. The Lancet 354:9184, pages 1122-1123.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Markers of Coagulation and Fibrinolysis as Measures of Disease Activity in Inflammatory Bowel Disease

Articles from other publishers (38)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Markers of Coagulation and Fibrinolysis as Measures of Disease Activity in Inflammatory Bowel Disease

Citations (38)

Articles from other publishers (38)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date